These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 21887350)

  • 1. Early presymptomatic and long-term changes of rest activity cycles and cognitive behavior in a MPTP-monkey model of Parkinson's disease.
    Vezoli J; Fifel K; Leviel V; Dehay C; Kennedy H; Cooper HM; Gronfier C; Procyk E
    PLoS One; 2011; 6(8):e23952. PubMed ID: 21887350
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lack of long-term changes in circadian, locomotor, and cognitive functions in acute and chronic MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) mouse models of Parkinson's disease.
    Fifel K; Dkhissi-Benyahya O; Cooper HM
    Chronobiol Int; 2013 Jul; 30(6):741-55. PubMed ID: 23758587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus).
    Taylor JR; Elsworth JD; Roth RH; Sladek JR; Redmond DE
    Neuroscience; 1997 Dec; 81(3):745-55. PubMed ID: 9316026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversible Pharmacological Induction of Motor Symptoms in MPTP-Treated Mice at the Presymptomatic Stage of Parkinsonism: Potential Use for Early Diagnosis of Parkinson's Disease.
    Khakimova GR; Kozina EA; Kucheryanu VG; Ugrumov MV
    Mol Neurobiol; 2017 Jul; 54(5):3618-3632. PubMed ID: 27194433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys.
    Slovin H; Abeles M; Vaadia E; Haalman I; Prut Y; Bergman H
    J Neurophysiol; 1999 Feb; 81(2):858-74. PubMed ID: 10036286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson's disease: A case series.
    Joers V; Masilamoni G; Kempf D; Weiss AR; Rotterman TM; Murray B; Yalcin-Cakmakli G; Voll RJ; Goodman MM; Howell L; Bachevalier J; Green SJ; Naqib A; Shaikh M; Engen PA; Keshavarzian A; Barnum CJ; Nye JA; Smith Y; Tansey MG
    Neurobiol Dis; 2020 Oct; 144():105027. PubMed ID: 32712266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Progression and recovery of Parkinsonism in a chronic progressive MPTP-induction model in the marmoset without persistent molecular and cellular damage.
    Franke SK; van Kesteren RE; Wubben JA; Hofman S; Paliukhovich I; van der Schors RC; van Nierop P; Smit AB; Philippens IH
    Neuroscience; 2016 Jan; 312():247-59. PubMed ID: 26431624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated intranigral MPTP administration: a new protocol of prolonged locomotor impairment mimicking Parkinson's disease.
    Reksidler AB; Lima MM; Dombrowski P; Andersen ML; Zanata SM; Andreatini R; Tufik S; Vital MA
    J Neurosci Methods; 2008 Jan; 167(2):268-77. PubMed ID: 17931705
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The intranasal administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a new rodent model to test palliative and neuroprotective agents for Parkinson's disease.
    Prediger RD; Aguiar AS; Moreira EL; Matheus FC; Castro AA; Walz R; De Bem AF; Latini A; Tasca CI; Farina M; Raisman-Vozari R
    Curr Pharm Des; 2011; 17(5):489-507. PubMed ID: 21375482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 1-Methyl-4-phenyl-1,2,3,6 tetrahydropyridine/probenecid impairs intestinal motility and olfaction in the early stages of Parkinson's disease in mice.
    Choi JG; Huh E; Ju IG; Kim N; Yun J; Oh MS
    J Neurol Sci; 2018 Sep; 392():77-82. PubMed ID: 30031172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Swim-test as a function of motor impairment in MPTP model of Parkinson's disease: a comparative study in two mouse strains.
    Haobam R; Sindhu KM; Chandra G; Mohanakumar KP
    Behav Brain Res; 2005 Sep; 163(2):159-67. PubMed ID: 15941598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The risk is in the air: Intranasal administration of MPTP to rats reproducing clinical features of Parkinson's disease.
    Prediger RD; Batista LC; Medeiros R; Pandolfo P; Florio JC; Takahashi RN
    Exp Neurol; 2006 Dec; 202(2):391-403. PubMed ID: 16908021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Opicapone enhances the reversal of MPTP-induced Parkinson-like syndrome by levodopa in cynomolgus monkeys.
    Bonifácio MJ; Sousa F; Soares-da-Silva P
    Eur J Pharmacol; 2021 Feb; 892():173742. PubMed ID: 33220276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
    Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
    Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous MPTP intoxication in the Göttingen minipig results in chronic parkinsonian deficits.
    Nielsen MS; Glud AN; Møller A; Mogensen P; Bender D; Sørensen JC; Doudet D; Bjarkam CR
    Acta Neurobiol Exp (Wars); 2016; 76(3):199-211. PubMed ID: 27685773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Atorvastatin improves cognitive, emotional and motor impairments induced by intranasal 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration in rats, an experimental model of Parkinson's disease.
    Castro AA; Wiemes BP; Matheus FC; Lapa FR; Viola GG; Santos AR; Tasca CI; Prediger RD
    Brain Res; 2013 Jun; 1513():103-16. PubMed ID: 23548600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
    Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
    Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breathing new life into neurotoxic-based monkey models of Parkinson's disease to study the complex biological interplay between serotonin and dopamine.
    Sgambato V
    Prog Brain Res; 2021; 261():265-285. PubMed ID: 33785131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys.
    Schneider JS; Kovelowski CJ
    Brain Res; 1990 Jun; 519(1-2):122-8. PubMed ID: 2397401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of intranasal exposure of MPTP in multiple doses on liver functions and transition from non-motor to motor symptoms in a rat PD model.
    Datta I; Mekha SR; Kaushal A; Ganapathy K; Razdan R
    Naunyn Schmiedebergs Arch Pharmacol; 2020 Feb; 393(2):147-165. PubMed ID: 31468077
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.